TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00804596

Intervention type: DEVICE
Group type: OTHER
Intervention: Apollo Blood Glucose Monitoring System
Description: Subjects with diabetes were rated for success in performing tasks with a new blood glucose monitoring system (BGMS). Also, subjects and healthcare professionals (HCPs) used the new blood glucose monitoring system with subject capillary blood. All blood glucose results were compared to a laboratory glucose method - Yellow Springs Instrument(YSI) Analyzer.
Study: NCT01663155

Intervention type: DEVICE
Intervention: chest x-ray with or without CAD, lose dose CT scan
Description: PA view, low dose CT scan
Study: NCT04071899

Intervention type: OTHER
Intervention: Scale vaidation
Description: It's just filling a scale in order to validate it in French

Intervention type: OTHER
Intervention: Scale vaidation
Description: It's just filling a scale in order to validate it in French
Study: NCT02219750

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: switch twice-daily insulin
Description: compare two different insuiln regimen in basal insuln base and premixed insulin.~NovoMix 30, drug class:biphasic insulins Lantus, drug class: long-acting insuiln Levemir, durg class: long-acting insulin NovoRapid, drug class: rapid-acting insulin
Study: NCT03649997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-61393215
Description: Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will be administered JNJ-61393215-matching placebo in Part 1, 2 and 3 of study as oral suspension.
Study: NCT01504204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene + benzoyl peroxide samples
Description: A sample size tube of the study medication, combination adapalene 0.1% plus benzoyl peroxide 2.5% gel, will be provided with instruction on proper application, including demonstration, at the first visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene + benzoyl peroxide from standard tube
Description: Subjects are instructed to apply the combination adapalene 0.1% plus benzoyl peroxide 2.5% gel once daily to all affected areas.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adapalene + benzoyl peroxide from standard tube
Description: Subjects are instructed to apply the combination adapalene 0.1% plus benzoyl peroxide 2.5% gel once daily to all affected areas.
Study: NCT03649997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will be administered JNJ-61393215-matching placebo in Part 1, 2 and 3 of study as oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will be administered JNJ-61393215-matching placebo in Part 1, 2 and 3 of study as oral suspension.
Study: NCT03603691

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: BMRC manual muscle test
Description: muscle scale grades muscle power on a scale of 0 to 5 in relation to the maximum expected for that muscle

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: BMRC manual muscle test
Description: muscle scale grades muscle power on a scale of 0 to 5 in relation to the maximum expected for that muscle

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: BMRC manual muscle test
Description: muscle scale grades muscle power on a scale of 0 to 5 in relation to the maximum expected for that muscle

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MicroFET2 handhold dynamometer
Description: MicroFET 2 Handheld Dynamometer is a force evaluation testing device to evaluate the strength of various muscle groups

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MicroFET2 handhold dynamometer
Description: MicroFET 2 Handheld Dynamometer is a force evaluation testing device to evaluate the strength of various muscle groups

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MicroFET2 handhold dynamometer
Description: MicroFET 2 Handheld Dynamometer is a force evaluation testing device to evaluate the strength of various muscle groups

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Modified Tardieu Scale
Description: Modified Tardieu Scale is to measure if there is spasticity present in a person's muscle and its response to movement
Study: NCT03513562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT04222972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pralsetinib
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Administered IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Administered IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Administered IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Administered IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Administered IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Administered IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-Paclitaxel
Description: Administered IV
Study: NCT02180035

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Symbiotic
Description: 6g sachet composition: Lactobacillus paracasei, Lactobacillus rhamnosus, Lactobacillus acidophillus, Bifidobacterium lactis and fructooligosaccharides. Each patient was instructed to consume two sachets per day, one in the morning and another before bedtime, diluted in 100 ml of filtered or boiled water at room temperature. The dietary supplement should be taken every day for 6 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin (placebo for symbiotic)
Description: 6g sachet of maltodextrin, a complex carbohydrate. Each patient was instructed to consume two sachets per day, one in the morning and another before bedtime, diluted in 100 ml of filtered or boiled water at room temperature. Placebo should be taken daily for 6 months.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Nutritional intervention
Description: Nutritional intervention consists of dietary prescription (nutritional eating plan) for healthy eating based on the Dietary Guidelines for the Brazilian Population and Clinical Manual on Food and Nutrition in HIV-infected Adults Care, both Brazil Ministry of Health guidelines, in addition to nutritional counseling for preexistent clinical conditions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional intervention
Description: Nutritional intervention consists of dietary prescription (nutritional eating plan) for healthy eating based on the Dietary Guidelines for the Brazilian Population and Clinical Manual on Food and Nutrition in HIV-infected Adults Care, both Brazil Ministry of Health guidelines, in addition to nutritional counseling for preexistent clinical conditions.
Study: NCT03649997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will be administered JNJ-61393215-matching placebo in Part 1, 2 and 3 of study as oral suspension.
Study: NCT00686894

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PDUS
Description: PDUS scored for each enthesitis every 2 weeks for 24 weeks.
Study: NCT03649997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-61393215
Description: Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-61393215
Description: Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as capsule.
Study: NCT00686894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: * 5 mg/kg~* IV~* Frequency : weeks 0,2,6
Study: NCT01059955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Phosphate Ophthalmic Solution (EGP-437)
Description: Transcleral iontophoretic delivery of dexamethasone phosphate ophthalmic solution. Dexamethasone phosphate ophthalmic solution as a ready to use 40 mg/mL solution (preservative free and intended for single-use only).
Study: NCT01059955

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone phosphate ophthalmic solution
Description: Transcleral iontophoretic delivery of dexamethasone phosphate ophthalmic solution. Dexamethasone phosphate ophthalmic solution as a ready to use 40 mg/mL solution (preservative free and intended for single-use only)
Study: NCT03365401

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: decompression surgery
Description: undertake decompression surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nonsurgical treatment
Description: complete on bed with prevention of complication
Study: NCT03964311

Intervention type: OTHER
Group type: OTHER
Intervention: Emergency Room Evaluation Tool (ER2)
Description: Emergency Room Evaluation Tool represents a screening method that will be used at the Emergency by nurses. This tool evaluates the health conditions of all the patients who are 75 years and over.
Study: NCT03364530

Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine-Oxaliplatin Regimen
Description: Vascularisation of hepatic tumors is almost exclusively provided by the hepatic artery.~Gemcitabine and oxaliplatin have a high rate of hepatic extraction during the first passage, thus allowing the drugs to reach high intra-tumoral concentrations with low systemic toxicity.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hepatic intra arterial chemotherapy
Description: The implantation of a hepatic arterial catheter has now been mastered by interventional radiologists and makes it possible to increase the intra-tumoral concentration of the drugs and probably to limit their systemic toxicity.~Very recently, we have reported that this combination in progressive IHC following systemic gemcitabine/oxaliplatin has led to partial responses and allowed certain patients to benefit from curative treatment.~This suggests that the intra-arterial approach increases the efficacy of these 2 drugs. For locally-advanced IHC, such a loco-regional approach is worth exploring in this poor-prognosis tumor.
Study: NCT04212234

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound propagation velocities, ultrasound fetal quality
Description: Obese pregnant women will be included before the second trimester fetal ultrasound examination.~Women will be allocated to one intervention group or to the control group. In the intervention group, the ultrasonographer will be able to use several ultrasound propagation velocities to perform the exam.~In the control group, exam will be performed using the conventional ultrasound velocity.~An exam will be considered to be complete if all the images recommended by national guideline are acquired. If ultrasound images are missing, other ultrasound exams may be performed until completeness is reached.~The protocol will be applied for the second and the third fetal ultrasound examination which are recommended by national guideline.~All scans will be evaluated by two independent experts who do not have performed any of the exams. They will evaluate the completeness of each exam. Each scan will be quoted using the quality score proposed by Salomon et al.
Study: NCT03713242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468 25 mg
Description: Administered as a tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468 25 mg (or 10 mg depending on interim results)
Description: Administered as a tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468 25 mg (or 10 mg depending on interim results)
Description: Administered as a tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468 25 mg (or 10 mg depending on interim results)
Description: Administered as a tablet.
Study: NCT03470506

Intervention type: OTHER
Intervention: Stool Samples
Description: Stool samples will be collected at baseline and 3 months to assess differences in microbiome composition between groups
Study: NCT00469443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 150mg/m2 IV on day 1 every 2 weeks for 10 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-Fluorouracil 400 mg/m2 infused over 10 min IV and 5-FU 600 mg/m2 infused over 22 hours IV, on Day 1 and 2 (De Grammont regimen), every 2 weeks for 10 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin 200 mg/m2 infused over 2 hours IV, on day 1 and 2 every 2 weeks for 10 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 2000mg/m2 p.o. daily, for days 1-14, every 3 weeks for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 5mg/kg IV on day 1 every 2 weeks for 10 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 7,5mg/kg IV on day 1 every 3 weeks for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 250mg/m2 IV on day 1 every 3 weeks for 6 cycles
Study: NCT01299636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM060184
Description: PM060184 administered intravenously (i.v.) over 10 minutes at a starting dose of 4 mg/m2/day on three consecutive days q2w (on Days 1-3 and 15-17) every 28 days.
Study: NCT04047342

Intervention type: BEHAVIORAL
Intervention: Welcome email
Description: Email

Intervention type: BEHAVIORAL
Intervention: Welcome email
Description: Email

Intervention type: BEHAVIORAL
Intervention: Loss frame
Description: Email
Study: NCT00386035

Intervention type: DRUG
Intervention: Delayed ART
Description: Participants follow a drug conservation (DC) regimen in which ART is stopped or deferred until CD4 cell count dropped below 250 cells/mm3, initiated until CD4 cell count is at least 350 cells/mm3, and then are followed by episodic ART based on CD4 cell count.

Intervention type: DRUG
Intervention: Continuous ART
Description: Group 2 participants follow a viral suppression (VS) regimen in which ART was continued to keep viral loads as low as possible, regardless of CD4 cell count.
Study: NCT04369742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Description: HCQ 400mg (2 tab) by mouth BID (day 1), 200mg (1 tab) by mouth BID (days 2-5)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Calcium citrate
Description: Calcium citrate 2 tablets (400mg) BID on day 1, 1 tablet (200mg) on days 2-5
Study: NCT02012257

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AMSA nerve block injectio
Description: Sites of injection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AMSA nerve block injectio
Description: Sites of injection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AMSA nerve block injectio
Description: Sites of injection
Study: NCT01861587

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: 20 minutes of either real or sham stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: 20 minutes of either real or sham stimulation
Study: NCT00768040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: 300 mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo once daily
Study: NCT04041401

Intervention type: OTHER
Intervention: PICU storybook
Description: Narrative and developmentally appropriate intervention
Study: NCT00955682

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine GSK134612
Description: One intramuscular dose (Booster)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningitec™
Description: One intramuscular dose (Booster)
Study: NCT02349841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem
Description: To administer 2g daily 8 hourly for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faropenem
Description: To adminster 600mg 8 hourly daily for 14 days
Study: NCT03649997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-61393215
Description: Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-61393215
Description: Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-61393215
Description: Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-61393215
Description: Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as capsule.
Study: NCT02349841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxycillin/clavulanic acid
Description: To administer 625mg 8 hourly daily for 14 days together with the faropenem and meropenem

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxycillin/clavulanic acid
Description: To administer 625mg 8 hourly daily for 14 days together with the faropenem and meropenem

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifafour e275
Description: To be taken as per the National TB treatment programme for 14 days
Study: NCT01388205

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-based Outdoor program
Description: 2 to 3 hour outdoor activities organized in conjunction with National Parks, Singapore
Study: NCT02468076

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (StarMed)
Description: Radiofrequency ablation into bile duct
Study: NCT02533011

Intervention type: OTHER
Intervention: HBP lab test
Description: Plasma level of Heparin Binding Protein will be evaluated on extra blood specimens already collected as part of standard of care.

Intervention type: OTHER
Intervention: HBP lab test
Description: Plasma level of Heparin Binding Protein will be evaluated on extra blood specimens already collected as part of standard of care.

Intervention type: OTHER
Intervention: HBP lab test
Description: Plasma level of Heparin Binding Protein will be evaluated on extra blood specimens already collected as part of standard of care.
Study: NCT01258738

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: etanercept
Description: In Period 1, subjects will receive in a prefilled syringe with 1.0 ml (test article Etanercept (SC) once weekly . Additionally they will continue to take the background non steroidal anti inflammatory drug(NSAID) in the tolerated dose agreed upon by the attending Physician.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Background NSAID
Description: Subject will continue to take a concomitant background non steroidal anti inflammatory drug(NSAID)as prescribed by their attending physician. The name and dose of this NSAID is the decision of the attending physician.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: In Period 1 will receive a prefilled syringe of Placebo for Etanercept Additionally they will continue to take the background non steroidal anti inflammatory drug(NSAID) in the tolerated dose agreed upon by the attending Physician.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Background NSAID
Description: Subject will continue to take a concomitant background non steroidal anti inflammatory drug(NSAID)as prescribed by attending physician (dose drug selection as tolerated and agreed upon by the attending Physician).
Study: NCT03637504

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MedActionPlan®
Description: web-based, mobile medication management application \[MedActionPlan® (MAP)\]
Study: NCT03603691

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Modified Tardieu Scale
Description: Modified Tardieu Scale is to measure if there is spasticity present in a person's muscle and its response to movement

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Modified Tardieu Scale
Description: Modified Tardieu Scale is to measure if there is spasticity present in a person's muscle and its response to movement
Study: NCT03637504

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: MedActionPlan®
Description: web-based, mobile medication management application \[MedActionPlan® (MAP)\]
Study: NCT03815201

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Group 2
Description: leucine-enriched protein supplementation during the first 1/2 hour post-training
Study: NCT03603691

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Fatigue Scale for Motor and Cognitive Functions
Description: Measures cognitive and motor fatigue for people with MS

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Fatigue Scale for Motor and Cognitive Functions
Description: Measures cognitive and motor fatigue for people with MS

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Fatigue Scale for Motor and Cognitive Functions
Description: Measures cognitive and motor fatigue for people with MS

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: numeric rating scale Fatigue
Description: visual analog scale that uses a scalar numbering system to objectify a patient's fatigue (0 = no fatigue; 10 = most extreme fatigue)

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: numeric rating scale Fatigue
Description: visual analog scale that uses a scalar numbering system to objectify a patient's fatigue (0 = no fatigue; 10 = most extreme fatigue)

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: numeric rating scale Fatigue
Description: visual analog scale that uses a scalar numbering system to objectify a patient's fatigue (0 = no fatigue; 10 = most extreme fatigue)
Study: NCT01906905

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Study: NCT04927507

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet plus nursing home rehabilitation
Description: The observation group was given the Internet plus nursing home rehabilitation mode.~Relying on mobile app and wechat public service platform, patients can get online guidance of rehabilitation training video through app and wechat, and get professional rehabilitation guidance at any time.
Study: NCT00003056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine and methotrexate